Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.

Oncotarget - 25 Oct 2016

Koppens Martijn A J, Bounova Gergana, Cornelissen-Steijger Paulien, de Vries Nienke, Sansom Owen J, Wessels Lodewyk F A, van Lohuizen Maarten

Abstract excerpt

EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light. To determine whether colorectal cancer cells respond to EZH2 inhibition and to explore which factors influence the degree of response, we treated a panel of 20 organoid lines derived from human colon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Indoles

Share to Organoids

Share to PAX2 Transcription Factor

Share to Pyridones

Share to X-linked Nuclear Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 27634879
DOI: 10.18632/oncotarget.12002
PMCID: PMC5342517

Genes

ATRX
BIK
MDM2
PAX2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.PMID 27634879Read ↗

Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technologySemantic proximity Read ↗

Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistanceSemantic proximity Read ↗

Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signallingSemantic proximity Read ↗

3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitorsSemantic proximity Read ↗

3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitorsSemantic proximity Read ↗

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsSemantic proximity Read ↗

Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer ProgressionSemantic proximity Read ↗

Hath1, Down-Regulated in Colon Adenocarcinomas, Inhibits Proliferation and Tumorigenesis of Colon Cancer CellsSemantic proximity Read ↗

Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cellsSemantic proximity Read ↗

Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem CellsSemantic proximity Read ↗

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).Semantic proximity Read ↗

Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.